A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs
A phase 3 trial of Lutetium[177Lu] Oxodotreotide Injection in neuroendocrine tumours, run by Sinotau Pharmaceutical Group, active and no longer recruiting.
Overview
A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs is a phase 3 interventional study registered as NCT05459844 by Sinotau Pharmaceutical Group, with 196 participants enrolled, started 2022-08-31 and due to reach its primary completion in 2024-06-26. Interventions recorded: Lutetium[177Lu] Oxodotreotide Injection and Octreotide LAR.
Similar pages
not linked directly; found by shared links- TrialA Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms
Shares Sinotau Pharmaceutical, Neuroendocrine tumours, Lutetium-177 and the tag pipeline.
- TrialStudy to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
Shares Pancreatic neuroendocrine tumours, Small intestinal neuroendocrine tumours, Neuroendocrine tumours, Lutetium-177 and the tag pipeline.
- TrialAn Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.
Shares Pancreatic neuroendocrine tumours, Lutetium-177 and the tag pipeline.
- TrialLutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE
Shares Pancreatic neuroendocrine tumours, Small intestinal neuroendocrine tumours, Neuroendocrine tumours, Lutetium-177 and the tag pipeline.
- TrialA Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
Shares Neuroendocrine tumours and the tag pipeline.
- TrialPhase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer
Shares Lutetium-177 and the tag pipeline.
- TrialA Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer
Shares Lutetium-177 and the tag pipeline.
- TrialStudy to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
Shares Lutetium-177 and the tag pipeline.